Insulin degludec/liraglutide (Xultophy®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015001184
English
Authors' recommendations:
Insulin degludec/liraglutide (Xultophy®) is recommended as an option for restricted use within NHS Wales. Insulin degludec/liraglutide (Xultophy®) is licensed for the treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a glucagon-like peptide protein-1 (GLP-1) receptor agonist or basal insulin do not provide adequate glycaemic control. Insulin degludec/liraglutide (Xultophy®) is restricted for use in combination with oral glucose-lowering medicinal products when these combined with basal insulin do not provide adequate glycaemic control. Insulin degludec/liraglutide (Xultophy®) is not recommended for use within NHS Wales outside of this subpopulation.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2544
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Insulin, Long-Acting
- Glucagon-Like Peptide 1
- Diabetes Mellitus, Type 2
- Blood Glucose
- Insulin
- Liraglutide
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.